


phenylene group optionally substituted by a second fluorine, chlorine or bromine atom or by a second C₁₋₃-alkyl group,

a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted in the carbon skeleton by a C₁₋₃-alkyl group,

R₁ denotes a C₁₋₃-alkyl group optionally substituted by an amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, phenyl, naphthyl, heteroaryl or 4- to 7-membered cycloalkyleneimino group,

 a C₃₋₇-cycloalkyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an amino, C₁₋₅-alkylamino, C₅₋₇-cycloalkylamino or phenyl-C₁₋₃-alkylamino group which may in each case be substituted at the amino-nitrogen atom by a benzoyl or phenylsulphonyl group or by a C₁₋₃-alkyl or C₁₋₃-alkylcarbonyl group optionally substituted in the C₁₋₃-alkyl moiety by a carboxy group,

a 4- to 7-membered cycloalkyleneiminocarbonyl or cycloalkyleneiminosulphonyl group optionally substituted by a C₁₋₃-alkyl group,

an aminosulphonyl group optionally substituted by one or two C₁₋₃-alkyl groups, a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, heteroaryloxy or heteroaryloxy-C₁₋₃-alkoxy group wherein the alkoxy moiety may be substituted in the 2 or 3 position in each case by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

a C₃₋₇-cycloalkoxy group, wherein the methylene group in the 3 or 4 position in a C₅₋₇-cycloalkoxy group may be replaced by an -NH group, and said -NH group may be optionally substituted

by a C₁₋₃-alkyl group which may be substituted in the 2 or 3 position by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, by a C₁₋₃-alkylcarbonyl, arylcarbonyl or arylsulphonyl group or

by an aminocarbonyl, C₁₋₃-alkylaminocarbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group, wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl, hydroxy or C₁₋₃-alkoxy group,

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group,

R₄ denotes a hydrogen atom or a C₁₋₃-alkyl group optionally substituted by a carboxy group and

R₅ denotes a cyano group or an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, said heteroaryl groups consisting of a 5-membered heteroaryl group optionally substituted by a C₁₋₃-alkyl group which contains in the heteroaromatic moiety,

an imino group optionally substituted by a C₁₋₃-alkyl group, or an oxygen or sulphur atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen, sulphur or nitrogen atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and two nitrogen atoms or

an oxygen or sulphur atom and two nitrogen atoms,

or a 6-membered heteroarylene group optionally substituted by a C₁₋₃-alkyl group which contains one or two nitrogen atoms in the heteroaromatic moiety,

an isomer or salt thereof.

2. (amended) The compound of formula I according to claim 1 wherein

one of the groups m or n denotes the number 0 and
the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a methyl, hydroxy, methoxy or benzyloxy group, which may be substituted by another methyl group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a methyl group substituted by a dimethylamino, pyrrolidino or imidazolyl group, wherein the imidazolyl moiety may be substituted by a methyl group,

an amino, C₁₋₅-alkylamino, cyclopentylamino or benzylamino group which may be substituted at the amino-nitrogen atom by a carboxy-C₁₋₂-alkyl, C₁₋₃-alkoxycarbonyl-C₁₋₂-alkyl, carboxy-C₁₋₂-alkylcarbonyl or C₁₋₃-alkoxycarbonyl-C₁₋₂-alkylcarbonyl group,

a benzoylamino or phenylsulphonylamino group,

a cyclopropyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl, piperidinocarbonyl, pyrrolidinosulphonyl or piperidinosulphonyl group,

a C₁₋₃-alkoxy group wherein the alkoxy moiety in the 2 or 3 position may be substituted in each case by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

a phenyl-C₁₋₃-alkoxy or pyridinyloxy group,

a C₅₋₇-cycloalkoxy group wherein the methylene group in the 3 or 4 position may be replaced by an -NH group, said -NH group may be substituted

by a C₁₋₃-alkyl or C₂₋₃-alkanoyl group,

by a C₂₋₃-alkanoyl or aminocarbonyl group wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl, hydroxy or methoxy group,

R₃ denotes a hydrogen atom or a methyl group,

R₄ denotes a hydrogen atom or a methyl or ethyl group optionally substituted by a carboxy or C₁₋₃-alkoxycarbonyl group and

R₅ denotes a cyano group or an amidino group optionally substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group,

or an isomer or salt thereof.

3. (amended) The compounds of formula I according to claim 1, wherein

one of the groups m or n denotes the number 0 and the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a methyl, hydroxy, methoxy or benzyloxy group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a cyclopropyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group, or a 4- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl, piperidinocarbonyl or pyrrolidinosulphonyl group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom or a methyl group,

R₃ denotes a hydrogen atom or a methyl group,

R₄ denotes a hydrogen atom or a methyl or ethyl group substituted by a carboxy, methoxycarbonyl or ethoxycarbonyl group and

R₅ denotes an amidino group optionally substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group,

or an the isomers or the salts thereof.

4. (amended) A compound of the formula I according to claim 1 selected from the following compounds:

(a) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

- (b) 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,
- (c) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,
- (d) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-carboxy-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,
- (e) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide and
- (f) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide,

wherein the amidino group may additionally be substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group, and the salts thereof.

5. (amended) A compound of formula 1 according to claim 1 as follows: 2-(5-Carbamidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide and the salts thereof.
6. (amended) A pharmaceutical composition comprising a compound according to claim 1 or a physiologically acceptable salt thereof according to claim 1 wherein R₅ denotes said amidino groups.
7. (amended) Pharmaceutical compositions containing a compound according to claim 1, wherein R₅ denotes said amidino groups.
8. (amended) A method of treating a patient in need of a pharmaceutical composition having an antithrombotic activity or factor Xa inhibiting activity by administering to said patient a therapeutically effective amount of a component according to claim 1 wherein R₅ denotes said amidino groups.